trial summary · NCT07490067
Mechanistic Clinical Trial Comparing the Pharmacokinetics/Pharmacodynamics of Metoprolol in Heart Failure With Reduced Ejection Fraction Patients With Low vs. High Polygenic Score
Personalizing Heart Failure Treatment With Genomics: A Clinical Trial to Understand the Mechanisms and Validate a Polygenic Risk Score for Beta-Blocker Response
Trial record from the TrialBase DB dataset, status RECRUITING, condition Heart Failure With Reduced Ejection Fraction, sponsored by University of Michigan. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
The purpose of this trial is to better understand how the beta-blocker metoprolol works in people with Heart Failure with Reduced Ejection Fraction (HFrEF) according to participants genetics. Participants will have the beta-blocker (BB) polygenic score calculated from genotype data. The score will be used to stratify the patients in the low and high polygenic score groups in the study. The hypotheses for this trial are: * HFrEF patients with high polygenic score will have weaker cardiovascular responses to metoprolol succinate than HFrEF patients with low polygenic score. * HFrEF patients with high polygenic score have lower steady-state plasma concentrations of metoprolol succinate than HFrEF patients with low polygenic score. * HFrEF patients with high polygenic score require higher metoprolol succinate plasma concentrations to achieve similar cardiovascular effects as those with low polygenic score.
Source record: https://clinicaltrials.gov/study/NCT07490067
Facts
| registry id | NCT07490067 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE4 |
| study type | INTERVENTIONAL |
| lead condition | Heart Failure With Reduced Ejection Fraction |
| sponsor | University of Michigan |
| sponsor class | OTHER |
| enrollment | 100 |
| start date | 2026-12 |
| primary completion | 2029-07 |
| completion | 2029-07 |
| results posted | not reported |
Conditions
- Heart Failure With Reduced Ejection Fraction
Interventions
- Metoprolol Succinate
- Beta-Blocker Polygenic Score
- Illumina Infinium Global Diversity Array with Enhanced Pharmacogenomics (PGx)
Countries
- United States
Intervention types: DEVICE, DRUG
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.